SBFM (Sunshine Biopharma) Moat Score: 2/10 (As of Jul. 01, 2026)


SBFM Sunshine Biopharma Inc SBFM
34 GF Score
Price $2.14
GF Value $7.14
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sunshine Biopharma Moat Score?

Sunshine Biopharma SBFM +3.32% 34 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.14 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Sunshine Biopharma ranks better than 81.67% on this metric.

Sunshine Biopharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Sunshine Biopharma has No Moat: Sunshine Biopharma Inc operates in a highly competitive industry with limited market share and no significant intellectual property or patents. The company lacks strong brand strength, customer loyalty, and cost advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sunshine Biopharma might have No Moat - Very weak/transient advantages.

Sunshine Biopharma  (NAS:SBFM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sunshine Biopharma Moat Score Related Terms

SBFM vs PRFX, CTTH, CVSI: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Biopharma Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Moat Score falls into.


SBFM
34GF Score
Sunshine Biopharma Inc SBFM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Sunshine Biopharma (SBFM) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sunshine Biopharma ranks #189 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Sunshine Biopharma's Moat Score too high?
Sunshine Biopharma's current Moat Score is 2. Based on the distribution chart, Sunshine Biopharma ranks #189 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's Moat Score compare to PRFX and CTTH?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #189 out of 1031 companies for Moat Score. This places Sunshine Biopharma in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sunshine Biopharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.14, compared to a current price of $2.14 — trading 70% below its estimated fair value. The current Moat Score is 2. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Biopharma (SBFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued. The current stock price of $2.14 is trading 70% below its estimated GF Value™ of $7.14. GuruFocus considers Sunshine Biopharma to be Possible Value Trap.

Key valuation signals for SBFM:

  • Moat Score: 2
  • GF Value™: $7.14 vs. price of $2.14 (70% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sunshine Biopharma Business Description

Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score

Get the complete analysis for SBFM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.14
Price
$7.14
GF Value